



Drug Utilization Review Board Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
January 19, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 and WebEx

[* Click HERE for Meeting Documents *](#)

Board Members Present:

Susan Abdel-Rahman, PharmD
Kimberly Eisenstein, MD
Lisa Pierce MD
Jennifer Passanise
Stacy Mangum
Ginger Nicol
Rick Kegler
Charlene Hyde, PharmD

Board Members Absent:

Sandra Bollinger, PharmD
Julie Ferguson

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of
Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Olivia Rush, PharmD, Program Integrity
Pharmacist
Elizabeth Sissom, RN, Clinical
Management
Lisa E. Smith, RFP Coordinator
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical
Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Denise Sappenfield, Benefit Program
Senior Specialist
Desiree Vitale
Hailey Korman, UMKC Student
Madison Nelson, Creighton Student

Contractors in Attendance:

April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP,
Conduent
Jennifer Colozza, PharmD, Conduent
Luke Boehmer, PharmD, Conduent
Megan Fast, PharmD, Conduent
Paul Fung, PharmD, Conduent
Sandra Kapur, PharmD, Conduent
Serena Barden, PharmD, BCPS,
Conduent
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Valerie Schmitz, RN, BSN Wipro
Ashley Lytton, RN, Wipro
Cassidy Jones, UMKC Student

Others Attending:

Adam Kopp
Anabelle Keohane
Ann Lucas
Ashlee
Ashleigh Holeman
Bill Eicholzer
Bobbi Bentz
Brett Lundsten
Brian Strickland
Bryan Dillon
Carrie Davis
Dave Miley
David Hershey
David Large
Donald Nopper
Garth Wright
Heather Higgins
James Baumann
Jamie Tobitt
Jasmine Inman
Jeff Knappen
Jessica Petrie
John Bullard
Karen Floeder
Kevin Mann
Kurt Hendrickson
Lindsay Bebout
Lisa
Marilyn Semenchuk
Matthew Lennertz
Melissa Basil
Michele Shirley
Ricki Roberson

Rob Kilo
Robert Firnberg
Roberto Pedraza
Sean Jones
Shauna Williams
Tami Sova
Tom Guyer
Vruti Patel

<p>Welcome, Introductions and Opening Remarks</p>	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with new pharmacy students, Madison, Hailey and Cassidy. Joshua also spoke on the promotion of Lisa Smith to RFP Coordinator. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the October 2021 meeting.</p> <p>Decision: The Board voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July-Nov 2021 Eligibles by Group - July-Nov 2021 Expenditures by Enrollment Group - July-Nov 2021 Expenditures by Service - FY22 Pharmacy Spend vs July-Nov 2021 Total Medicaid Spend - FY22 Pharmacy Expenditures - Top 4 Drug Classes per FY22 - Pharmacy Expenditures/Eligibles per FY (2015 – 2021) - Hep C Spend and Utilization FY18 – FYTD22 - Mavyret Expenditures - Synagis Expenditures FY19 – FYTD22 - Tamiflu Expenditures - FY19 – FYTD22 Rare Disease Expenditures - Continuous Glucose Monitor policy updates – Susan asked for utilization numbers; MHD to follow up - Reminder that MHD now accepts and edits a diagnosis code submitted on the point of sale claims - Pharmacy Signature Log Requirements – hot tip went out 12/15/21 - Streamlining older edits to help decrease call volume to the helpdesk and overall enhanced workflow for all those involved - Duplicative therapy utilization is high – working on a step wise efforts to decrease; meeting with others outside of MHD - Enhancing education efforts with hot tips and blasts; SMART therapy example; AUD is next on the list of educational materials

	<ul style="list-style-type: none"> - COVID home test coverage - Oral antivirals – EUA does not allow for pharmD to prescribe – they can dispense; we will pay a penny for the ingredient cost and then they will be reimbursed through the dispensing fee
Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the presented new drug recommendations with no revisions.</p>

Opioid Policy Review	
<p>High Risk Therapies Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board. - Discussion arose around: <ul style="list-style-type: none"> o CNMP for physical therapy – MHD to send out to group o Breakdown of how we have shifted utilization o DisposeRx – patient access and standing orders - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Morphine Milligram Equivalent (MME) Accumulation Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioid Dependence Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment was provided by: <ul style="list-style-type: none"> o Lindsay Bebout with Indivior on Sublocade <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioid Emergency Reversal Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Opioids, Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioids, Short Acting Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Tramadol-Like Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

Clinical and Fiscal Edit Review	
<p align="center">Clinical & Fiscal Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o 15 Day Supply Oral Oncology Fiscal Edit o Butalbital Combinations without Codeine Clinical Edit o Butalbital Combinations Excessive Therapy Edit o Diabetic Supply Quantity Limit Fiscal Edit o Out-of-State, Non-Bordering Pharmacies Fiscal Edit o Selzentry Clinical Edit - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">15 Day Supply Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Acetaminophen Cumulative Dose Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antipsychotics, 1st Generation (Typical) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Antipsychotics, 2nd Generation (Atypical) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment was provided by: <ul style="list-style-type: none"> o Lindsay Bebout with Indivior on Perseris yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Benzodiazepine, Select Oral Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>BiDil Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Biosimilar vs. Reference Products Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Corlanor Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Empaveli Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Jamie Tobitt with Apellis on Empaveli yielded time back <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Extended Supply Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">High Cost Medications Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Kerendia Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Non-Oral Contraceptives Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Pompe Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Spinal Muscular Atrophy (SMA) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Preferred Drug List Edit Review</p>	
<p>Preferred Drug Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Alzheimer’s Agents, AChEIs and NMDA Receptor Antagonists o Anticonvulsants, Dravet Syndrome o Antiemetics, THC Derivatives o Anti-Parkinsonism, MAO-B Inhibitors o Anti-Parkinsonism, Non-Ergot Dopamine Agonists o GI Motility Agents, Chronic o Somatostatin Analogs - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Matt Stroh with Zogenix on Fintepla <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antiandrogenic Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Antiemetics, 5-HT3 and NK1 Injectables</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anti-Migraine, Alternative Oral Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anti-Migraine, Serotonin (5-HT1) Receptor Agonists</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antiretroviral Therapy (ART)</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Bile Salt Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Calcitonin Gene-Related Peptide (CGRP) Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Fibromyalgia Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Glucagon Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: Vruti Patel with Xeris Pharmaceuticals on Gvoke <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Hereditary Angioedema Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Homozygous Familial Hypercholesterolemia (HoFH)</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - The Board recommended to add the AHA guidelines to the reference section to help providers navigate the algorithm – MHD to take back and update the proposal. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Neuropathic Pain Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose around the system ability to override clinical criteria where we know the pharmacy can override (i.e. pregnancy – we know it’s not a perfect system to determine if a participant is still pregnant) – MHD is working on system updates. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>NSAIDs</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Sedative Hypnotics</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Skeletal Muscle Relaxants</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Dave Miley with Teva on Austedo yielded time back o John Deason III with Neurocrine Biosciences on Ingrezza o Gregory Mattingly with Washington University on Ingrezza o Ahmed Taranissi on Ingrezza <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and April 2022 meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 1st Quarter 2022 (July, August, September) - Top 25 Drugs by Paid Number 1st Quarter 2022 (July, August, September) - Call Center User Statistics November 2021 - CyberAccess Logging Information - New Drug Statistics November 2021
<p>Motion to Close</p>	<p>Rick Kegler motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Utilization Review Board is scheduled via hybrid meeting (in person and WebEx) on Wednesday, April 20, 2022.</p>

Roll Call for January 19, 2022					
	<u>Action Item</u>				
<u>Board Member</u>	October Meeting Minutes	All Recommendations: Opioid Policy Review Edits	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	Y	Y	Y	Y	Y
Charlene Heyde	A	SY	Y	Y	SY
Sandra Bollinger	A	A	A	A	A
Julie Ferguson	A	A	A	A	A
Lisa Pierce	MY	MY	SY	SY	Y
Jennifer Passanise	Y	Y	Y	Y	Y
Stacy Mangum	Y	Y	Y	Y	Y
Ginger Nicol	Y	Y	Y	Y	Y
Rick Kegler	SY	Y	MY	MY	MY
Kim Eisenstein	Y	Y	Y	Y	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain